Research
Hormonal
Activation of PPARγ by thiazolidinediones (TZDs) like pioglitazone and rosiglitazone improves insulin sensitivity and glucose homeostasis, primarily by promoting fatty acid storage in adipose tissue and enhancing glucose uptake in skeletal muscle.
TZDs like pioglitazone activate PPARγ to help your body handle sugar better. They work by moving fat storage to your皮下 fat (subcutaneous) rather than your liver and muscles, which reduces insulin resistance. This improves blood sugar control but may lead to weight gain.
GoodSupportsHIGH confidence
PPARγ plays a vital role in glucose homeostasis, including in the enhancement of SKM sensitization to insulin, improving glucose-stimulated insulin secretion in pancreatic β-cells and increasing gluconeogenesis in the liver... Another way to improve insulin signaling by PPARγ is to transfer lipids out of circulation, liver, and SKM and into WAT, which may cause adipogenesis in the WAT.
Why this rating
Supported by clinical use of TZDs and extensive research on PPARγ knockout and activation.
Source
PPARs as Nuclear Receptors for Nutrient and Energy Metabolism
Fan Hong et al. · Molecules · 2019
DOI 10.3390/molecules24142545
narrative_reviewCited 221×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Activation of PPARα by fibrate agonists (e.g., fenofibrate, ciprofibrate) reduces plasma triglycerides and LDL-C while increasing HDL-C, primarily by accelerating fatty acid oxidation and ketone body production in the liver.Good
- Activation of PPARβ/δ by agonists like GW501516 improves fatty acid oxidation and glucose utilization in skeletal muscle, shifting muscle fiber type from fast-twitch glycolytic to slow-twitch oxidative, thereby enhancing exercise capacity and metabolic flexibility.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →